Cargando…

Effect of Cumulative Dexamethasone Dose during Concomitant Chemoradiation on Lymphopenia in Patients with Newly Diagnosed Glioblastoma

BACKGROUND: Lymphopenia frequently occurs after concomitant chemoradiation (CCRT) in patients with glioblastoma (GBM) and is associated with worse overall survival (OS). A few studies have tried to identify risk factors for lymphopenia; however, the results were not clear. We aimed to identify poten...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Changik, Ahn, Stephen, Park, Jae-Sung, Song, Jin Ho, Hong, Yong-Kil, Jeun, Sin-Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Brain Tumor Society; The Korean Society for Neuro-Oncology; The Korean Society for Pediatric Neuro-Oncology 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595853/ https://www.ncbi.nlm.nih.gov/pubmed/32648384 http://dx.doi.org/10.14791/btrt.2020.8.e12

Ejemplares similares

Impact of Body Mass Index on Survival Outcome in Patients with Newly Diagnosed Glioblastoma: A Retrospective Single-Center Study
por: Cha, Jun-Yong, et al.
Publicado: (2021)

Compassionate use of recombinant human IL‐7‐hyFc as a salvage treatment for restoring lymphopenia in patients with recurrent glioblastoma
por: Ahn, Stephen, et al.
Publicado: (2022)

Standard 6-week chemoradiation for elderly patients with newly diagnosed glioblastoma
por: Vaugier, Loïg, et al.
Publicado: (2021)

Lymphopenia during chemoradiation—foe or friend
por: Patil, Vijay M, et al.
Publicado: (2020)

Lymphopenia and Radiation Dose to Circulating Lymphocytes With Neoadjuvant Chemoradiation in Esophageal Squamous Cell Carcinoma
por: So, Tsz Him, et al.
Publicado: (2020)

Feasibility of hippocampus-sparing VMAT for newly diagnosed glioblastoma treated by chemoradiation: pattern of failure analysis
por: Wee, Chan Woo, et al.
Publicado: (2020)

Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI
por: Ly, K. Ina, et al.
Publicado: (2018)

Immune Control Despite Protracted Lymphopenia After Chemoradiation in an Elite Controller
por: Reiss, Kim A., et al.
Publicado: (2016)

Cytomegalovirus-Specific Immunotherapy for Glioblastoma Treatments
por: Ahn, Jaehyun, et al.
Publicado: (2022)

Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis
por: Roh, Tae Hoon, et al.
Publicado: (2017)

Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI
por: Ly, K. Ina, et al.
Publicado: (2019)

Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era
por: Byun, Hwa Kyung, et al.
Publicado: (2019)

Outcomes in Newly Diagnosed Elderly Glioblastoma Patients after Concomitant Temozolomide Administration and Hypofractionated Radiotherapy
por: Nguyen, Ludovic T., et al.
Publicado: (2013)

ACT-10 TREATMENT FOR GLIOBLASTOMA RECURRED AFTER CONCOMITANT CHEMORADIATION THERAPY WITH TEMOZOLOMIDE AND THEIR PROGNOSIS
por: Mori, Kanji, et al.
Publicado: (2019)

Splenic irradiation contributes to grade ≥ 3 lymphopenia after adjuvant chemoradiation for stomach cancer
por: Lee, Shing Fung, et al.
Publicado: (2022)

Avelumab in newly diagnosed glioblastoma
por: Jacques, Francois H, et al.
Publicado: (2021)

Prognostic significance of concomitant radiotherapy in newly diagnosed glioblastoma multiforme: a multivariate analysis of 116 patients
por: Okumus, Nilgun Ozbek, et al.
Publicado: (2012)

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome
por: Weller, Michael, et al.
Publicado: (2016)

NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma
por: Batchelor, Tracy T, et al.
Publicado: (2023)

Comparative study of concomitant chemoradiation versus concomitant chemoradiation followed by high-dose-rate intraluminal brachytherapy in locally advanced esophageal carcinoma: a single institutional study
por: Halder, Anirban, et al.
Publicado: (2018)

HLA polymorphisms and risk of glioblastoma in Koreans
por: Choi, Sang-Soo, et al.
Publicado: (2021)

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
por: Vieito, Maria, et al.
Publicado: (2022)

Reduced Weekly Subcutaneous Doses of Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Newly Diagnosed Multiple Myeloma
por: Ashrafi, Farzaneh, et al.
Publicado: (2020)

Advances in the treatment of newly diagnosed glioblastoma
por: Theeler, Brett J., et al.
Publicado: (2015)

A Review of Newly Diagnosed Glioblastoma
por: Oronsky, Bryan, et al.
Publicado: (2021)

Newly Diagnosed Glioblastoma in Elderly Patients
por: Yuen, Carlen A., et al.
Publicado: (2022)

Polymorphisms of Killer Ig-like Receptors and the Risk of Glioblastoma
por: Choi, Haeyoun, et al.
Publicado: (2023)

The cumulative dose-dependent effects of metformin on the development of tuberculosis in patients newly diagnosed with type 2 diabetes mellitus
por: Heo, Eunyoung, et al.
Publicado: (2021)

Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis: Erratum
Publicado: (2017)

Fatal Gastrointestinal Hemorrhage in a Young Boy with Newly Diagnosed Metastatic Medulloblastoma on High Dose Dexamethasone
por: Wong, Victor, et al.
Publicado: (2014)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Final Report on Clinical Outcomes and Tumor Recurrence Patterns of a Pilot Study Assessing Efficacy of Belinostat (PXD-101) with Chemoradiation for Newly Diagnosed Glioblastoma
por: Xu, Karen, et al.
Publicado: (2022)

Continuous treatment with lenalidomide and low‐dose dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial
por: Lu, Jin, et al.
Publicado: (2017)

Correction: Newly Diagnosed Glioblastoma in Elderly Patients
por: Yuen, Carlen A., et al.
Publicado: (2022)

Interstitial photodynamic therapy for newly diagnosed glioblastoma
por: Quach, Stefanie, et al.
Publicado: (2023)

Lenalidomide and low‐dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study
por: Suzuki, Kenshi, et al.
Publicado: (2016)

The Efficacy of High-Dose Dexamethasone vs. Other Treatments for Newly Diagnosed Immune Thrombocytopenia: A Meta-Analysis
por: Xiao, Qirong, et al.
Publicado: (2021)

Higher single dose of bortezomib plus thalidomide and dexamethasone is a promising therapy for newly diagnosed multiple myeloma
por: Xu, Peipei, et al.
Publicado: (2019)

Lymphopenia, Lymphopenia-Induced Proliferation, and Autoimmunity
por: Sheu, Ting-Ting, et al.
Publicado: (2021)

Comparison of bortezomibcyclophosphamide- dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
por: Ciftciler, Rafiye, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cn2n11j5pobkjukhekal17a4ma